| Chapter title |
Progress in Cancer Immunotherapy
|
|---|---|
| Chapter number | 4 |
| Book title |
Progress in Cancer Immunotherapy
|
| Published in |
Advances in experimental medicine and biology, May 2016
|
| DOI | 10.1007/978-94-017-7555-7_4 |
| Pubmed ID | |
| Book ISBNs |
978-9-40-177553-3, 978-9-40-177555-7
|
| Authors |
Yang, Fan, Jin, Hao, Wang, Jian, Sun, Qian, Yan, Cihui, Wei, Feng, Ren, Xiubao, Fan Yang, Hao Jin, Jian Wang, Qian Sun, Cihui Yan, Feng Wei, Xiubao Ren |
| Abstract |
Adoptive cellular therapy (ACT) with various lymphocytes or antigen-presenting cells is one stone in the pillar of cancer immunotherapy, which relies on the tumor-specific T cell. The transfusion of bulk T-cell population into patients is an effective treatment for regression of cancer. In this chapter, we summarize the development of various strategies in ACT for cancer immunotherapy and discuss some of the latest progress and obstacles in technical, safety, and even regulatory aspects to translate these technologies to the clinic. ACT is becoming a potentially powerful approach to cancer treatment. Further experiments and clinical trials are needed to optimize this strategy. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 17% |
| Student > Master | 7 | 13% |
| Student > Postgraduate | 5 | 9% |
| Researcher | 3 | 6% |
| Student > Ph. D. Student | 3 | 6% |
| Other | 3 | 6% |
| Unknown | 23 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 15% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Agricultural and Biological Sciences | 4 | 8% |
| Immunology and Microbiology | 3 | 6% |
| Chemical Engineering | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 23 | 43% |